MCID: ESS003
MIFTS: 70

Essential Thrombocythemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Essential Thrombocythemia

MalaCards integrated aliases for Essential Thrombocythemia:

Name: Essential Thrombocythemia 12 76 53 25 59 29 6 15
Essential Thrombocytosis 53 25 59 37
Hemorrhagic Thrombocythemia 12 53
Hereditary Thrombocythemia 12 59
Thrombocythemia, Essential 44 73
Familial Thrombocytosis 12 59
Primary Thrombocythemia 53 25
Primary Thrombocytosis 12 25
Essential Thrombocythaemia 12
Idiopathic Thrombocythemia 53
Thrombocythemia Essential 55
Familial Thrombocythemia 59
Et 59

Characteristics:

Orphanet epidemiological data:

59
essential thrombocythemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (United States),1-5/10000 (Sweden); Age of onset: All ages; Age of death: normal life expectancy;
familial thrombocytosis
Inheritance: Autosomal dominant,X-linked recessive; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:



Summaries for Essential Thrombocythemia

NIH Rare Diseases : 53 Essential thrombocythemia belongs to a group of conditions called myeloproliferative disorders. Myeloproliferative disorders cause platelets, white blood cells and red blood cells to grow abnormally in the bone marrow (the soft tissue inside the hollow part of bones that helps form blood cells). In essential thrombocythemia, the body produces too many platelet cells. The signs and symptoms vary from person to person, but most people with essential thrombocythemia do not have any symptoms when the platelet cell count first increases. The main signs and symptoms include:Increased production of megakaryocytes (a type of cell in the bone marrow that is responsible for making platelets) Enlargement of the spleen (splenomegaly), and  Bleeding in several parts of the body and/or clotting episodes such as strokes, pain in the legs  and difficulty breathing. Other symptoms may include weakness, headaches, or burning, tingling or prickling sensations in the skin. Some people have episodes of severe pain, redness, and swelling, especially in the hands and feet. Essential thrombocythemia is caused by mutations in the JAK2 (most frequently) and CALR genes, and rarely, the disease is caused by mutations in the MPL, THPO, and TET2 genes.  Treatment may include medication such as hydroxyurea, anagrelide, or interferon-alpha.  Most people with the disease can live long lives.  In very rare cases, essential  thrombocythemia can transform into either primary myelofibrosis or acute myeloid leukemia.

MalaCards based summary : Essential Thrombocythemia, also known as essential thrombocytosis, is related to thrombocythemia 1 and acquired von willebrand syndrome. An important gene associated with Essential Thrombocythemia is THPO (Thrombopoietin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Anagrelide and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are myocardial infarction and splenomegaly

Disease Ontology : 12 A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results in the overproduction of platelets.

Genetics Home Reference : 25 Essential thrombocythemia is a condition characterized by an increased number of platelets (thrombocythemia). Platelets (thrombocytes) are blood cell fragments involved in blood clotting. While some people with this condition have no symptoms, others develop problems associated with the excess platelets.

Wikipedia : 76 Essential thrombocythemia (ET) is a rare chronic blood condition characterised by the overproduction of... more...

Related Diseases for Essential Thrombocythemia

Diseases in the Essential Thrombocythemia family:

Thrombocythemia 1 Thrombocythemia 2
Thrombocythemia 3

Diseases related to Essential Thrombocythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 33.7 CALR MPL SH2B3 THPO
2 acquired von willebrand syndrome 33.7 JAK2 VWF
3 myeloproliferative neoplasm 32.6 ABL1 CALR JAK2 MPL SH2B3 STAT5B
4 thrombocytosis 32.6 EPO IL3 JAK2 MPL SELP TET2
5 thrombosis 32.3 JAK2 SELP THBD VWF
6 polycythemia 31.7 CALR CD177 EPO IL3 JAK2 MPL
7 purpura 31.3 MPL THBD THPO VWF
8 thrombophilia 31.3 JAK2 PPBP THBD VWF
9 thrombocytopenia due to platelet alloimmunization 31.2 MPL SELP THPO
10 thrombocytopenic purpura, autoimmune 31.2 IFNA2 MPL SELP THPO
11 stroke, ischemic 31.1 PPBP SELP THBD VWF
12 splenomegaly 31.1 EPO IFNA2 JAK2 MPL
13 myeloid leukemia 31.1 ABL1 IL3 JAK2 TET2 TP53
14 systemic mastocytosis 31.0 IFNA2 JAK2 TET2
15 thrombotic thrombocytopenic purpura 31.0 SELP THBD VWF
16 hairy cell leukemia 30.9 IFNA1 IFNA2 IL3
17 chronic myelomonocytic leukemia 30.8 ASXL1 JAK2 TET2
18 megakaryocytic leukemia 30.7 IL3 JAK2 THPO TP53
19 polycythemia vera 30.5 ABL1 CALR CD177 EPO IFNA1 IL3
20 refractory anemia 30.2 ASXL1 EPO IL3 JAK2 MPL TET2
21 aplastic anemia 29.6 ASXL1 EPO IL3 MPL TET2 THPO
22 myelodysplastic syndrome 29.4 ABL1 ASXL1 EPO IL3 JAK2 MPL
23 myelofibrosis 29.0 ASXL1 CALR CD177 EPO IFNA1 IFNA2
24 leukemia, acute myeloid 28.9 ABL1 ASXL1 IL3 JAK2 MIR223 MPL
25 leukemia, chronic myeloid 28.4 ABL1 CD177 EPO IFNA1 IFNA2 IL3
26 inherited predisposition to essential thrombocythemia 12.3
27 unilateral absence of a pulmonary artery 11.1 THBD VWF
28 thrombocytopenia 3 11.1 MPL THPO
29 autoimmune disease of blood 11.1 MPL THPO VWF
30 plantar wart 11.1 IFNA1 TP53
31 thrombocytopenia-absent radius syndrome 11.0 CALR JAK2 MPL THPO
32 lymphomatoid granulomatosis 11.0 IFNA1 IFNA2
33 squamous papillomatosis 11.0 IFNA1 IFNA2
34 portal hypertension 11.0 JAK2 THPO VWF
35 thrombocythemia with distal limb defects 11.0
36 primary thrombocytopenia 11.0 MPL SELP THPO VWF
37 amegakaryocytic thrombocytopenia, congenital 10.9 IL3 MPL THPO
38 dyskeratosis congenita, autosomal dominant 6 10.9 MPL THPO
39 folic acid deficiency anemia 10.9 EPO TET2 THPO
40 al amyloidosis 10.9 IL3 VWF
41 peripheral vascular disease 10.9 PPBP SELP THBD VWF
42 cellular neurofibroma 10.9 ABL1 TP53
43 blood platelet disease 10.8 JAK2 MPL SELP THPO VWF
44 myelodysplastic myeloproliferative cancer 10.8 ASXL1 JAK2 TET2
45 cryoglobulinemia, familial mixed 10.8 IFNA1 IFNA2
46 refractory anemia with excess blasts 10.8 ASXL1 TET2
47 behcet syndrome 10.8 IFNA1 IFNA2 JAK2 THBD
48 chromosome 5q deletion syndrome 10.8 EPO TET2
49 retinitis pigmentosa and erythrocytic microcytosis 10.7 EPO IL3 JAK2
50 vasculitis 10.7 IFNA2 THBD VWF

Graphical network of the top 20 diseases related to Essential Thrombocythemia:



Diseases related to Essential Thrombocythemia

Symptoms & Phenotypes for Essential Thrombocythemia

Human phenotypes related to Essential Thrombocythemia:

59 32 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myocardial infarction 59 32 hallmark (90%) Very frequent (99-80%) HP:0001658
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0001744
3 transient ischemic attack 59 32 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0002326
4 acute leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002488
5 myelodysplasia 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002863
6 prolonged bleeding time 59 32 hallmark (90%) Very frequent (99-80%) HP:0003010
7 paresthesia 59 32 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0003401
8 arterial thrombosis 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004420
9 increased megakaryocyte count 59 32 hallmark (90%) Very frequent (99-80%) HP:0005513
10 abnormal platelet morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0011875
11 myelofibrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011974
12 amaurosis fugax 59 32 hallmark (90%) Very frequent (99-80%) HP:0100576
13 chest pain 59 32 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0100749
14 venous thrombosis 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004936
15 hyperhidrosis 59 32 frequent (33%) Frequent (79-30%) HP:0000975
16 pruritus 59 32 frequent (33%) Frequent (79-30%) HP:0000989
17 visual field defect 59 32 occasional (7.5%) Occasional (29-5%) HP:0001123
18 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
19 dysarthria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001260
20 syncope 59 32 occasional (7.5%) Occasional (29-5%) HP:0001279
21 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
22 abnormal bleeding 59 32 hallmark (90%) Very frequent (99-80%) HP:0001892
23 thrombocytosis 59 32 hallmark (90%) Very frequent (99-80%) HP:0001894
24 pulmonary arterial hypertension 59 32 occasional (7.5%) Occasional (29-5%) HP:0002092
25 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
26 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
27 acute myeloid leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0004808
28 spontaneous abortion 59 32 occasional (7.5%) Occasional (29-5%) HP:0005268
29 chronic myelogenous leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0005506
30 abnormality of thrombocytes 59 Very frequent (99-80%)
31 abnormality of bone marrow cell morphology 59 Very frequent (99-80%)
32 abnormality of the cerebral vasculature 59 Very frequent (99-80%)
33 cerebral ischemia 59 Frequent (79-30%)
34 occlusive vascular disease 59 Frequent (79-30%)
35 peripheral arterial stenosis 32 frequent (33%) HP:0004950

MGI Mouse Phenotypes related to Essential Thrombocythemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 MPL ABL1 SELP ASXL1 CALR SH2B3
2 hematopoietic system MP:0005397 10.17 ABL1 MPL SELP ASXL1 SH2B3 STAT5B
3 homeostasis/metabolism MP:0005376 10.03 JAK2 MPL ABL1 SELP ASXL1 CALR
4 immune system MP:0005387 10 ABL1 MPL SELP ASXL1 SH2B3 STAT5B
5 liver/biliary system MP:0005370 9.61 ABL1 SELP ASXL1 STAT5B EPO TET2
6 mortality/aging MP:0010768 9.4 JAK2 MPL ABL1 SELP ASXL1 CALR

Drugs & Therapeutics for Essential Thrombocythemia

Drugs for Essential Thrombocythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
4
Zinc Approved, Investigational Phase 4 7440-66-6 23994
5 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
6
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-86-4 3871
7 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
12
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
13
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
14
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
15
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
16
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dalteparin Approved Phase 3 9005-49-6
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
24
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
25
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
26
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
27 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
28
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
29
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
30
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
31
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
32
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
33
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
34
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
35
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
38 Anesthetics Phase 3
39 Anesthetics, Dissociative Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
43 Excitatory Amino Acid Antagonists Phase 3
44 Excitatory Amino Acids Phase 3
45 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
3 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
7 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
8 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
9 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
10 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
11 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
12 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
13 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
14 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
15 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
16 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
19 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
22 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
24 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
25 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
26 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
27 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
28 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
29 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
30 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
31 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
32 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
34 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
35 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
36 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
37 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
38 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
39 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
40 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Completed NCT00413634 Phase 2 anagrelide hydrochloride
41 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib
42 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
43 Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT01236638 Phase 2 Momelotinib
44 Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Completed NCT00935987 Phase 1, Phase 2 CYT387
45 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis Completed NCT01369498 Phase 2 Simtuzumab;Ruxolitinib
46 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
47 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2 SAR302503
48 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
49 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Completed NCT01445769 Phase 2 Ruxolitinib
50 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF Completed NCT01392443 Phase 2 Ruxolitinib

Search NIH Clinical Center for Essential Thrombocythemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thrombocythemia, essential

Genetic Tests for Essential Thrombocythemia

Genetic tests related to Essential Thrombocythemia:

# Genetic test Affiliating Genes
1 Essential Thrombocythemia 29 CALR SH2B3 THPO

Anatomical Context for Essential Thrombocythemia

MalaCards organs/tissues related to Essential Thrombocythemia:

41
Bone, Bone Marrow, Myeloid, Spleen, Skin, Liver, Endothelial

Publications for Essential Thrombocythemia

Articles related to Essential Thrombocythemia:

(show top 50) (show all 861)
# Title Authors Year
1
A rare CALR variant mutation and a review of CALR in essential thrombocythemia. ( 29411299 )
2018
2
Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations. ( 29521158 )
2018
3
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. ( 29734070 )
2018
4
Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis. ( 29703677 )
2018
5
Genomics of clonal evolution in a case of essential thrombocythemia. ( 28604261 )
2018
6
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ( 29427319 )
2018
7
Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. ( 29603799 )
2018
8
Mastocytosis With Associated Essential Thrombocythemia. ( 29566880 )
2018
9
Essential Thrombocythemia Presenting as Paraneoplastic Glomerulonephritis. ( 29962681 )
2018
10
Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients. ( 29332224 )
2018
11
ASXL1 mutations in Chinese patients with essential thrombocythemia. ( 29725364 )
2018
12
Chronic recurrent pulmonary thromboembolism in a patient with essential thrombocythemia, complicating acute right ventricular infarct. ( 29318735 )
2018
13
Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. ( 29971894 )
2018
14
Essential thrombocythemia treatment algorithm 2018. ( 29321520 )
2018
15
Polycythemia vera and essential thrombocythemia: algorithmic approach. ( 29194068 )
2018
16
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. ( 29181548 )
2018
17
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. ( 29891835 )
2018
18
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. ( 29622658 )
2018
19
Cardiac Surgery Using Hypothermic Circulatory Arrest in a Case of Essential Thrombocythemia. ( 29925725 )
2018
20
Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia. ( 29668550 )
2018
21
Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia. ( 29609040 )
2018
22
Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the Literature. ( 29705369 )
2018
23
A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia. ( 28587547 )
2018
24
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. ( 29556018 )
2018
25
Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. ( 29751169 )
2018
26
Anagrelide and the CALR mutation allele burden in essential thrombocythemia. ( 29949532 )
2018
27
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B<sub>2</sub> assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. ( 29880847 )
2018
28
Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2<sup>V617F</sup>-positive Essential Thrombocythemia. ( 29521303 )
2018
29
The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: a comparison in a large-scale cohort. ( 29405428 )
2018
30
Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article. ( 29979407 )
2018
31
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ( 29313725 )
2018
32
Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia. ( 29390868 )
2018
33
Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. ( 28543356 )
2017
34
Efficacy and safety of anagrelide in childhood essential thrombocythemia. ( 28707720 )
2017
35
A Novel Approach to Essential Thrombocythemia and Cardiac Surgery. ( 28219560 )
2017
36
[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease]. ( 28766534 )
2017
37
Putti MC, Pizzi M, Bertozzi I, et al. Bone marrow histology for the diagnosis of essential thrombocythemia in children: a multicenter Italian study. Blood. 2017;129(22):3040-3042. ( 28818981 )
2017
38
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. ( 29254200 )
2017
39
Abdominal surgery in patients with essential thrombocythemia: A case report and systematic review of literature. ( 29381999 )
2017
40
Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. ( 28049641 )
2017
41
Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review. ( 28285408 )
2017
42
Acute transmural myocardial infarction by coronary embolism in a patient with JAK2 V617F-positive essential thrombocythemia. ( 28692109 )
2017
43
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. ( 28601551 )
2017
44
Mutant calreticulin causes essential thrombocythemia. ( 29179429 )
2017
45
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. ( 28622623 )
2017
46
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. ( 28248312 )
2017
47
Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. ( 28395806 )
2017
48
Efficacy of interferon-alpha in essential thrombocythemia during pregnancy. ( 28194492 )
2017
49
A novel germ-line mutation of c-mpl gene in a sporadic case of essential thrombocythemia. ( 28391042 )
2017
50
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. ( 28685840 )
2017

Variations for Essential Thrombocythemia

ClinVar genetic disease variations for Essential Thrombocythemia:

6
(show top 50) (show all 155)
# Gene Variation Type Significance SNP ID Assembly Location
1 THPO THPO, IVS3, G-C, +1 single nucleotide variant Pathogenic
2 THPO THPO, 1-BP DEL, 3252G deletion Pathogenic
3 THPO THPO, 516G-T single nucleotide variant Pathogenic
4 MPL NM_005373.2(MPL): c.117G> T (p.Lys39Asn) single nucleotide variant risk factor rs17292650 GRCh37 Chromosome 1, 43803807: 43803807
5 MPL NM_005373.2(MPL): c.117G> T (p.Lys39Asn) single nucleotide variant risk factor rs17292650 GRCh38 Chromosome 1, 43338136: 43338136
6 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh37 Chromosome 1, 43814979: 43814979
7 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh38 Chromosome 1, 43349308: 43349308
8 SH2B3 NM_005475.2(SH2B3): c.622G> C (p.Glu208Gln) single nucleotide variant Pathogenic rs202080221 GRCh37 Chromosome 12, 111856571: 111856571
9 SH2B3 NM_005475.2(SH2B3): c.622G> C (p.Glu208Gln) single nucleotide variant Pathogenic rs202080221 GRCh38 Chromosome 12, 111418767: 111418767
10 CALR NM_004343.3(CALR): c.1092_1143del52 (p.Leu367Thrfs) deletion Pathogenic GRCh37 Chromosome 19, 13054565: 13054616
11 CALR NM_004343.3(CALR): c.1092_1143del52 (p.Leu367Thrfs) deletion Pathogenic GRCh38 Chromosome 19, 12943751: 12943802
12 ATG2B; BDKRB1; BDKRB2; C14orf132; GSKIP; LOC107984703; TCL1A; TUNAR NC_000014.9: g.95696766_96390792dup duplication Likely pathogenic GRCh37 Chromosome 14, 96163103: 96857129
13 ATG2B; BDKRB1; BDKRB2; C14orf132; GSKIP; LOC107984703; TCL1A; TUNAR NC_000014.9: g.95696766_96390792dup duplication Likely pathogenic GRCh38 Chromosome 14, 95696766: 96390792
14 MPL NM_005373.2(MPL): c.210G> A (p.Pro70=) single nucleotide variant Likely benign rs6086 GRCh37 Chromosome 1, 43803900: 43803900
15 MPL NM_005373.2(MPL): c.210G> A (p.Pro70=) single nucleotide variant Likely benign rs6086 GRCh38 Chromosome 1, 43338229: 43338229
16 MPL NM_005373.2(MPL): c.92T> C (p.Leu31Pro) single nucleotide variant Uncertain significance rs878854771 GRCh38 Chromosome 1, 43338111: 43338111
17 MPL NM_005373.2(MPL): c.92T> C (p.Leu31Pro) single nucleotide variant Uncertain significance rs878854771 GRCh37 Chromosome 1, 43803782: 43803782
18 MPL NM_005373.2(MPL): c.844G> A (p.Gly282Arg) single nucleotide variant Uncertain significance rs878854770 GRCh37 Chromosome 1, 43805788: 43805788
19 MPL NM_005373.2(MPL): c.844G> A (p.Gly282Arg) single nucleotide variant Uncertain significance rs878854770 GRCh38 Chromosome 1, 43340117: 43340117
20 MPL NM_005373.2(MPL): c.1309-10C> T single nucleotide variant Benign/Likely benign rs139486615 GRCh37 Chromosome 1, 43814504: 43814504
21 MPL NM_005373.2(MPL): c.1309-10C> T single nucleotide variant Benign/Likely benign rs139486615 GRCh38 Chromosome 1, 43348833: 43348833
22 MPL NM_005373.2(MPL): c.1653+3G> A single nucleotide variant Benign/Likely benign rs149625825 GRCh37 Chromosome 1, 43817977: 43817977
23 MPL NM_005373.2(MPL): c.1653+3G> A single nucleotide variant Benign/Likely benign rs149625825 GRCh38 Chromosome 1, 43352306: 43352306
24 MPL NM_005373.2(MPL): c.1794C> T (p.Cys598=) single nucleotide variant Benign/Likely benign rs143457144 GRCh38 Chromosome 1, 43352658: 43352658
25 MPL NM_005373.2(MPL): c.1794C> T (p.Cys598=) single nucleotide variant Benign/Likely benign rs143457144 GRCh37 Chromosome 1, 43818329: 43818329
26 THPO NM_000460.3(THPO): c.1030A> G (p.Thr344Ala) single nucleotide variant Benign/Likely benign rs35794435 GRCh38 Chromosome 3, 184372545: 184372545
27 THPO NM_000460.3(THPO): c.1030A> G (p.Thr344Ala) single nucleotide variant Benign/Likely benign rs35794435 GRCh37 Chromosome 3, 184090333: 184090333
28 THPO NM_000460.3(THPO): c.229-17_229-14dupTTCC duplication Likely benign rs55827759 GRCh38 Chromosome 3, 184373596: 184373599
29 THPO NM_000460.3(THPO): c.229-17_229-14dupTTCC duplication Likely benign rs55827759 GRCh37 Chromosome 3, 184091384: 184091387
30 THPO NM_000460.3(THPO): c.*18G> A single nucleotide variant Uncertain significance rs180680111 GRCh37 Chromosome 3, 184090283: 184090283
31 THPO NM_000460.3(THPO): c.*18G> A single nucleotide variant Uncertain significance rs180680111 GRCh38 Chromosome 3, 184372495: 184372495
32 MPL NM_005373.2(MPL): c.196C> T (p.Leu66=) single nucleotide variant Uncertain significance rs886046349 GRCh38 Chromosome 1, 43338215: 43338215
33 MPL NM_005373.2(MPL): c.196C> T (p.Leu66=) single nucleotide variant Uncertain significance rs886046349 GRCh37 Chromosome 1, 43803886: 43803886
34 MPL NM_005373.2(MPL): c.543T> C (p.Gly181=) single nucleotide variant Benign/Likely benign rs17572791 GRCh38 Chromosome 1, 43339422: 43339422
35 MPL NM_005373.2(MPL): c.543T> C (p.Gly181=) single nucleotide variant Benign/Likely benign rs17572791 GRCh37 Chromosome 1, 43805093: 43805093
36 MPL NM_005373.2(MPL): c.1051C> T (p.Arg351Cys) single nucleotide variant Uncertain significance rs201998783 GRCh38 Chromosome 1, 43346515: 43346515
37 MPL NM_005373.2(MPL): c.1051C> T (p.Arg351Cys) single nucleotide variant Uncertain significance rs201998783 GRCh37 Chromosome 1, 43812186: 43812186
38 MPL NM_005373.2(MPL): c.1337G> A (p.Gly446Glu) single nucleotide variant Uncertain significance rs561724539 GRCh38 Chromosome 1, 43348871: 43348871
39 MPL NM_005373.2(MPL): c.1337G> A (p.Gly446Glu) single nucleotide variant Uncertain significance rs561724539 GRCh37 Chromosome 1, 43814542: 43814542
40 MPL NM_005373.2(MPL): c.1570C> T (p.Leu524=) single nucleotide variant Likely benign rs146372205 GRCh38 Chromosome 1, 43352220: 43352220
41 MPL NM_005373.2(MPL): c.1570C> T (p.Leu524=) single nucleotide variant Likely benign rs146372205 GRCh37 Chromosome 1, 43817891: 43817891
42 MPL NM_005373.2(MPL): c.*573G> A single nucleotide variant Likely benign rs192016153 GRCh38 Chromosome 1, 43353345: 43353345
43 MPL NM_005373.2(MPL): c.*573G> A single nucleotide variant Likely benign rs192016153 GRCh37 Chromosome 1, 43819016: 43819016
44 MPL NM_005373.2(MPL): c.*924C> G single nucleotide variant Uncertain significance rs886046354 GRCh37 Chromosome 1, 43819367: 43819367
45 MPL NM_005373.2(MPL): c.*924C> G single nucleotide variant Uncertain significance rs886046354 GRCh38 Chromosome 1, 43353696: 43353696
46 MPL NM_005373.2(MPL): c.*1603A> C single nucleotide variant Likely benign rs142139493 GRCh38 Chromosome 1, 43354375: 43354375
47 MPL NM_005373.2(MPL): c.*1603A> C single nucleotide variant Likely benign rs142139493 GRCh37 Chromosome 1, 43820046: 43820046
48 MPL NM_005373.2(MPL): c.95C> T (p.Ala32Val) single nucleotide variant Uncertain significance rs886046348 GRCh38 Chromosome 1, 43338114: 43338114
49 MPL NM_005373.2(MPL): c.95C> T (p.Ala32Val) single nucleotide variant Uncertain significance rs886046348 GRCh37 Chromosome 1, 43803785: 43803785
50 MPL NM_005373.2(MPL): c.854-3T> C single nucleotide variant Likely benign rs201514537 GRCh38 Chromosome 1, 43340384: 43340384

Expression for Essential Thrombocythemia

Search GEO for disease gene expression data for Essential Thrombocythemia.

Pathways for Essential Thrombocythemia

Pathways related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 ABL1 CALR CD177 IFNA1 IFNA2 IL3
2
Show member pathways
13.56 EPO IFNA1 IFNA2 IL3 JAK2 MPL
3
Show member pathways
13.34 EPO IFNA1 IFNA2 IL3 JAK2 MPL
4
Show member pathways
13.25 IFNA1 IFNA2 IL3 JAK2 STAT5B TP53
5
Show member pathways
12.83 EPO IFNA1 IFNA2 IL3 JAK2 TP53
6 12.69 ABL1 EPO IFNA1 IFNA2 IL3 JAK2
7
Show member pathways
12.67 IFNA1 IFNA2 JAK2 STAT5B TP53
8
Show member pathways
12.55 ABL1 CD177 IFNA1 IFNA2 IL3 JAK2
9
Show member pathways
12.46 IFNA1 IFNA2 JAK2 STAT5B TP53
10 12.45 IFNA1 IL3 JAK2 MPL STAT5B
11
Show member pathways
12.35 EPO IFNA1 IFNA2 IL3 JAK2 MPL
12
Show member pathways
12.19 IFNA1 IFNA2 JAK2 STAT5B
13
Show member pathways
12.1 IFNA1 IFNA2 JAK2 STAT5B
14
Show member pathways
12.04 EPO IL3 JAK2 SH2B3 STAT5B
15 11.99 ABL1 IFNA1 IFNA2 JAK2 SH2B3 TP53
16 11.8 EPO IFNA2 IL3 MPL SH2B3 THPO
17 11.79 JAK2 STAT5B THBD
18
Show member pathways
11.78 MPL THPO VWF
19 11.78 JAK2 MPL STAT5B THPO
20 11.77 EPO IL3 THPO
21
Show member pathways
11.76 EPO JAK2 SH2B3 STAT5B
22 11.54 JAK2 SELP STAT5B
23 11.44 ABL1 EPO IFNA1 IFNA2 IL3 JAK2
24 11.2 ABL1 JAK2 TP53
25
Show member pathways
11.13 JAK2 SELP STAT5B

GO Terms for Essential Thrombocythemia

Cellular components related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CALR CD177 EPO IFNA1 IFNA2 IL3
2 extracellular space GO:0005615 9.32 CALR EPO IFNA1 IFNA2 IL3 MIR223

Biological processes related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.92 ABL1 CD177 IFNA1 IFNA2 JAK2
2 positive regulation of cell proliferation GO:0008284 9.91 CALR EPO IL3 JAK2 STAT5B
3 regulation of signaling receptor activity GO:0010469 9.85 EPO IFNA1 IFNA2 IL3 PPBP THPO
4 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ABL1 IL3 JAK2 STAT5B
5 regulation of cell adhesion GO:0030155 9.65 ABL1 JAK2 STAT5B
6 response to lipopolysaccharide GO:0032496 9.65 EPO JAK2 PPBP SELP THBD
7 positive regulation of DNA replication GO:0045740 9.63 CALR EPO IL3
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 ABL1 IL3 JAK2 TP53
9 B cell proliferation GO:0042100 9.58 ABL1 IFNA1 IFNA2
10 embryonic hemopoiesis GO:0035162 9.56 IL3 SH2B3
11 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.55 JAK2 STAT5B
12 negative regulation of cell-cell adhesion GO:0022408 9.54 ABL1 JAK2
13 cytokine-mediated signaling pathway GO:0019221 9.5 IFNA1 IFNA2 IL3 JAK2 MPL STAT5B
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 EPO IFNA2 IL3 JAK2
15 thrombopoietin-mediated signaling pathway GO:0038163 9.43 MPL THPO
16 blood coagulation GO:0007596 9.17 CD177 IFNA1 IFNA2 JAK2 SH2B3 THBD

Molecular functions related to Essential Thrombocythemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 CD177 TP53 VWF
2 chaperone binding GO:0051087 9.33 CALR TP53 VWF
3 type I interferon receptor binding GO:0005132 9.32 IFNA1 IFNA2
4 protein tyrosine kinase activity GO:0004713 9.26 ABL1 IL3 JAK2 STAT5B
5 cytokine activity GO:0005125 9.1 EPO IFNA1 IFNA2 IL3 PPBP THPO

Sources for Essential Thrombocythemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....